Analysts' Actions: FB HPQ MAR GPS ZNGA

Rockwood (ROC) rated new Buy at BofA/Merrill. $58 price target. Company can see earnings growth accelerate in 2014.

Skyworks (SWKS) rated new Buy at Lazard. $30 price target. Stock can recover and the company emerges as the clear winner from the iPhone 5.

Thermo Fisher (TMO) upgraded at Wells to Outperform from Market Perform, Wells Fargo said. Company is leveraged to a strong mass spectrometer market.

Vanguard Natural (VNR) rated new Buy at UBS. $33 price target. Growing steadily and paying monthly.

Zynga (ZNGA) downgraded at Baird to Neutral, Robert Baird said. $3 price target. Company cut its guidance again. Zynga downgraded at BofA/Merrill from Neutral to Underperform, Bank of America/Merrill Lynch said. $2.70 price target. Estimates also cut, given the company's new guidance.

STOCK COMMENTS / EPS CHANGES

Alexion Pharmaceuticals (ALXN) numbers raised at Oppenheimer. Shares of ALXN now seen reaching $134, Oppenheimer said. Estimates also raised on headroom in the orphan disease franchise. Outperform rating.

Endo (ENDP) numbers cut at UBS. Shares of ENDP now seen reaching $45, UBS said. Estimates also lowered following investor day. Buy rating.

Facebook (FB) estimates, target reduced at JP Morgan. Shares of FB now seen reaching $28, according to JP Morgan. Estimates also cut, given the company's exposure to ZNGA. Overweight rating.

Gap (GPS) estimates, target increased at Piper. GPS estimates were raised through 2014, Piper Jaffray said. Company is carrying sales momentum into the Fall season. Overweight rating and new $42 price target.

Informatica (INFA) numbers cut at JMP. INFA estimates were reduced through 2013, JMP Securities said. Company cut guidance for a second straight quarter. Outperform rating and new $38 price target.

Impax Labs (IPXL) numbers boosted at BofA/Merrill. Shares of IPXL now seen reaching $25, according to Bank of America/Merrill Lynch said. Estimates also upped, as the company is seeing higher generic sales. Underperform rating.

Marriott (MAR) estimates, target raised at Nomura. Shares of MAR now seen reaching $48, according to Nomura. Estimates also increased, given higher expected RevPAR growth. Buy rating.

>To submit a news tip, email: [e-mail].

READERS ALSO LIKE:

>>The Next Big Thing in Biotech: Celgene

>>Biotech Stock Mailbag: Sarepta Bear Story, Vertex, Osiris

Follow TheStreet on Twitter and become a fan on Facebook.

This article was written by a staff member of TheStreet.

« First ‹ Previous 1 2